

## Special Issue

# Cellular and Molecular Pathogenesis of Hepatobiliary Diseases

### Message from the Guest Editor

Hepatobiliary disease (HBD) occurs in the liver and biliary tract and is caused by various risk factors, such as infection, toxins, metabolic disorders, alcohol intake, and heart failure. Severe or chronic damage to the hepatobiliary system can result in tissue fibrosis, which can progress to cirrhosis and eventually lead to life-threatening conditions such as liver failure and hepatobiliary cancer. Hence, early intervention for HBD is important to prevent HBD from progressing to end-stage HBD. This Special Issue will focus on understanding the cellular and molecular pathogenesis of HBD, which greatly contributes to the development of novel therapeutic strategies that are more specific and effective for the treatment of HBD patients. Authors are invited to submit original research or review articles related to this Special Issue. Potential topics include but are not limited to:

- Risk factors related to the development of HBD;
- Novel cellular and molecular mechanisms of HBD pathogenesis;
- Potential biomarkers for predicting the progression and response to therapy of HBD;
- Currently available therapies for the treatment of HBD and future directions.

### Guest Editor

Dr. Jeongeun Hyun

Institute of Tissue Regeneration Engineering, Dankook University,  
Cheonan, Republic of Korea

### Deadline for manuscript submissions

closed (30 September 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/103791](https://mdpi.com/si/103791)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).